Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. Needham & Company LLC's price target indicates a potential upside of 285.36% from the company's previous close.
Separately, Truist Financial dropped their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $9.32.
Get Our Latest Research Report on Autolus Therapeutics
Autolus Therapeutics Stock Down 3.2%
Autolus Therapeutics stock traded down $0.09 during mid-day trading on Monday, reaching $2.60. The company had a trading volume of 1,320,103 shares, compared to its average volume of 1,751,803. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.00. The company has a 50 day moving average of $2.12 and a 200-day moving average of $1.89. The firm has a market cap of $690.63 million, a price-to-earnings ratio of -2.95 and a beta of 1.81.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. On average, analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of AUTL. Two Sigma Investments LP lifted its stake in Autolus Therapeutics by 23.8% in the fourth quarter. Two Sigma Investments LP now owns 906,767 shares of the company's stock valued at $2,131,000 after buying an additional 174,485 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Autolus Therapeutics by 146.7% in the fourth quarter. Renaissance Technologies LLC now owns 618,942 shares of the company's stock valued at $1,455,000 after purchasing an additional 368,071 shares during the last quarter. Legal & General Group Plc increased its holdings in Autolus Therapeutics by 392.0% during the fourth quarter. Legal & General Group Plc now owns 297,736 shares of the company's stock worth $697,000 after buying an additional 237,224 shares during the last quarter. Millennium Management LLC increased its holdings in Autolus Therapeutics by 91.6% during the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock worth $3,885,000 after buying an additional 790,437 shares during the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Autolus Therapeutics by 169.9% in the fourth quarter. Cetera Investment Advisers now owns 356,222 shares of the company's stock valued at $837,000 after purchasing an additional 224,222 shares during the last quarter. Institutional investors own 72.83% of the company's stock.
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Recommended Stories

Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.